CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and obesity.

Sanofi’s last job before breaking up for the Christmas holiday? Putting the finishing touches on a $2.5bn agreement to buy vaccine firm Dynavax.

The FDA approved Agios Pharmaceuticals’ drug mitapivat to treat thalassemia on Tuesday, under the name Aqvesme, following a three-month delay and a missed deadline. The

Sanofi is set to supplement its vaccine offering with the acquisition of Dynavax Technologies for $2.2 billion in cash, the companies said Wednesday. Separately, Sanofi

Plus, news about BioMarin and Cassava. 💊 Gilead opts into Assembly Bio’s genital herpes programs: As a result, Gilead will pay Assembly $35 million based